Xuetongsu attenuates synovial inflammation in rheumatoid arthritis by inhibiting the IL-23/IL-17/NF-κB inflammatory axis
These findings suggest that XTS targets IL-23 to inhibit the IL-23/IL-17/NF-κB axis, offering new insights into RA treatment. This study provides the first evidence that the natural product XTS exerts anti-inflammatory effects in RA by specifically targeting IL-23. Our findings reveal its molecular mechanism and establish a novel paradigm for developing IL-23-targeted RA therapies, advancing traditional medicine modernization.
Authors
- Juan Huang (ORCID: https://orcid.org/0000-0002-5181-1116)
- Hao Zheng (ORCID: https://orcid.org/0000-0001-5760-1278)
- Bin Li (ORCID: https://orcid.org/0000-0001-6083-9535)
- Hanwen Yuan (ORCID: https://orcid.org/0000-0002-2288-7656)
- Wei Wang (ORCID: https://orcid.org/0000-0003-0876-2205)
- Yuxin Chen (ORCID: https://orcid.org/0000-0002-5906-2877)
- Yupei Yang (ORCID: https://orcid.org/0000-0002-1436-4775)
- Huanghe Yu
- Mengyun Wang
- Yasi Deng
Institutions
- Hunan University of Traditional Chinese Medicine (CN)
- Changsha Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3389/fphar.2025.1615519
- Citations
- 9
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 15.01
Funders
- National Natural Science Foundation of China
- Hunan University
- Natural Science Foundation of Hunan Province
- Hunan University of Chinese Medicine
- Research and Innovation Foundation
- Science and Technology Program of Hunan Province